文献速递血液透析通路

血液透析通路手术后阿片类药物使用模式及持续使用风险

Opioid use patterns and persistent use after hemodialysis access surgery.
PubMed 文献 · J Vasc Surg · 2025-06-06

该回顾性队列研究纳入28404例接受血液透析通路建立的Medicare参保且既往未使用阿片类药物的终末期肾病患者,评估术后持续阿片类药物使用风险。50.2%患者在通路建立时填写了阿片类药物处方,其中23.1%处方量≥42片5mg羟考酮当量。与未填写处方者相比,接受≥42片者持续使用风险为1.28倍(95%CI 1.08-1.52),而≤20片者无显著风险增加(HR 1.00;95%CI 0.85-1.18)。

要点

  • 50.2%患者在血液透析通路建立时填写阿片类药物处方。
  • 23.1%的处方≥42片5mg羟考酮当量(≥2周用量)。
  • ≥42片者持续使用风险为未处方者的1.28倍(95%CI 1.08-1.52)。

核心结论

  • 鉴于血液透析通路手术可能导致持续阿片类药物使用,考虑制定保守的透析通路疼痛管理正式推荐可能是值得的。

研究设计与样本

  • 回顾性队列研究,纳入2015年4月至2019年6月期间因终末期肾病开始血液透析的美国肾脏数据系统中Medicare参保且既往未使用阿片类药物的患者,共28404例,中位年龄72岁(25th, 75th百分位66, 79岁),男性15322例(53.9%)。

主要发现

  • 28404例患者中,14265例(50.2%)在通路建立时填写了阿片类药物处方,其中3289份处方(23.1%)为≥42片5mg羟考酮当量(即≥2周处方)。
  • 接受≥42片5mg羟考酮当量的患者相对于未填写阿片类药物处方者,持续阿片类药物使用的风险为1.28倍(95%CI 1.08-1.52)。
  • 接受≤20片5mg羟考酮当量的患者与持续阿片类药物使用风险增加无关(HR 1.00;95%CI 0.85-1.18)。

关键数值与推荐

  • 持续阿片类药物使用定义为手术后90至180天内的阿片类药物处方。
  • 阿片类药物剂量以5mg羟考酮当量表示,≥42片相当于≥2周处方。

临床怎么用

  • 原文未报告临床实践建议,仅提出制定保守的血液透析通路疼痛管理正式推荐可能值得考虑。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated the risk of persistent opioid use related to opioid pain management for hemodialysis access creation and identify patterns of opioid dosage and use. METHODS: This retrospective cohort study included Medicare-enrolled opioid-naïve patients in the US Renal Data System who initiated hemodialysis for end-stage kidney disease between April 2015 and June 2019. Persistent opioid use was defined as an opioid prescription 90 to 180 days after surgery. The Cox proportional hazards model used censored patients at the time of hospitalization, subsequent hemodialysis access procedures, death, and end of Medicare enrollment. A mixed-effect logistic regression modeled opioid prescription, and a mixed-effect linear regression modeled opioid quantity in 5-mg hydrocodone equivalents. RESULTS: A total of 28,404 patients (median age, 72 years; 25th, 75th percentile, 66, 79 years; 15,322 men [53.9%]) underwent index access creation, of whom 14,265 patients filled an opioid prescription at access creation (50.2%), with 3289 opioid prescriptions (23.1%) for ≥42 tablets of 5-mg hydrocodone equivalents (ie, ≥2 weeks prescription). Patients receiving ≥42 tablets of 5-mg hydrocodone equivalents (≥2 weeks) had 1.28 times the risk of persistent opioid use (95% confidence interval, 1.08-1.52) relative to those who did not fill an opioid prescription. In contrast, receipt of 20 or fewer tablets of 5-mg hydrocodone equivalents was not associated with an increased risk of persistent opioid use (hazard ratio 1.00; 95% confidence interval, 0.85-1.18). CONCLUSIONS: Given the risk of persistent opioid use stemming from hemodialysis access procedures, the development of formal recommendations for conservative hemodialysis access pain management may be worth considering.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Copeland TP, Nahm WJ, Woo K, et al. Opioid use patterns and persistent use after hemodialysis access surgery. J Vasc Surg. 2025. PMID: 40482897. doi:10.1016/j.jvs.2025.05.207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。